You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK):JS012注射液獲得藥物臨牀試驗申請受理通知書
格隆匯 09-10 22:19

格隆匯9月10日丨君實生物(01877.HK)宣佈,公司收到中國國家藥品監督管理局核准簽發的《受理通知書》,JS012注射液(項目代號"JS012")的臨牀試驗申請獲得受理。

JS012注射液的活性成分為重組人源化抗Claudin18.2單克隆抗體,可靶向作用於Claudin18.2靶點,抑制相關信號通路,通過激活抗體依賴細胞介導的細胞毒性(ADCC)及補體依賴的細胞毒性(CDC)殺傷腫瘤細胞,擬用於治療晚期惡性腫瘤,例如胃癌及胰腺癌等。

Claudin蛋白是構成細胞緊密連接的重要分子,該蛋白家族已經發現27個成員。Claudin 18即屬於Claudin蛋白家族中的一員,在人體內由Claudin18基因編碼,其具有兩個蛋白亞型,分別為Claudin18.1和Claudin18.2,均具有組織特異性。其中Claudin18.2在正常組織中主要表達在分化的胃黏膜上表皮細胞上,不表達在胃幹細胞上,然而在多種原發性惡性腫瘤如胃癌、胰腺癌、食管腺癌、結腸癌、肝癌等及其轉移灶中,均發現了Claudin18.2的異常激活和過度表達,由於Claudin18.2在正常組織表達的高度特異性及在多種癌症中的激活表達,使其成為了極具潛力的靶點。截至公吿日期,全球尚無同類靶點產品獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account